Contract with Customer, Asset, Net, Current - Not Material

No definition available.

Name:	revv_ContractWithCustomerAssetNetCurrentNotMaterial
Namespace Prefix:	revv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Customer Deposits Received in Advance of Transfer of Control, Current

+ References

No definition available.

+ Details

Name:	revv_CustomerDepositsInAdvanceOfTransferOfControlCurrent
Namespace Prefix:	revv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Remaining Performance Obligations

+ References

No definition available.

+ Details

Name:	revv_RemainingPerformanceObligations
Namespace Prefix:	revv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Unbilled Receivables

+ References

No definition available.

+ Details

Name:	revv_UnbilledReceivables
Namespace Prefix:	revv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- References

No definition available.

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 91
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479777/606-10-55-91

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-7

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=revv_DiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=revv_LifeSciencesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_LifeSciencesSolutionsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_SoftwareMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_ReproductiveHealthMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_AppliedGenomicsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	revv_MajorGoodsserviceLinesAxis=revv_ImmunodiagnosticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Revenue (Details) - USD ($) $ in Thousands	Sep. 28, 2025	Sep. 29, 2024	Sep. 28, 2025	Sep. 29, 2024	Dec. 29, 2024
Disaggregation of Revenue [Line Items]
Segment revenue	$ 698,949	$ 684,049	$ 2,083,995	$ 2,025,654
Unbilled Receivables	95,500		95,500		$ 80,600
Deferred Revenue	224,000		224,000		$ 212,800
Customer Deposits in Advance of Transfer of Control, Current	$ 19,500		$ 19,500
Remaining Performance Obligations			Transaction price allocated to the remaining performance obligationsThe Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts.
Contract with Customer, Asset and Liability [Abstract]
Contract with Customer, Asset, Net, Current - Not Material	The Company had no material contract assets as of September 28, 2025 and December 29, 2024.
Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 307,277	302,325	$ 935,486	904,462
Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	202,397	182,038	587,821	545,188
Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	189,275	199,686	560,688	576,004
Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	356,127	345,249	1,034,880	1,001,815
Diagnostics [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	129,190	116,849	376,049	352,619
Diagnostics [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	119,065	106,923	344,169	318,065
Diagnostics [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	107,872	121,477	314,662	331,131
Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	342,822	338,800	1,049,115	1,023,839
Life Sciences [Member] \| Americas [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	178,087	185,476	559,437	551,843
Life Sciences [Member] \| Europe [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	83,332	75,115	243,652	227,123
Life Sciences [Member] \| Asia [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	81,403	78,209	246,026	244,873
Life Sciences Solutions [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	290,541	295,455	875,046	884,849
Life Sciences Solutions [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Life Sciences Solutions [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	290,541	295,455	875,046	884,849
Software [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	52,281	43,345	174,069	138,990
Software [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Software [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	52,281	43,345	174,069	138,990
Reproductive health [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	143,388	133,683	405,761	388,336
Reproductive health [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	143,388	133,683	405,761	388,336
Reproductive health [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	0	0	0	0
Applied genomics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue		684,049		2,025,654
Immunodiagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	212,739	211,566	629,119	613,479
Immunodiagnostics [Member] \| Diagnostics [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	212,739	211,566	629,119	613,479
Immunodiagnostics [Member] \| Life Sciences [Member]
Disaggregation of Revenue [Line Items]
Segment revenue	$ 0	$ 0	$ 0	$ 0